Zobrazeno 1 - 10
of 15
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
Alok A. Khorana, Fahrettin Covut, Yihong Zhou, Shafia Rahman, Shab E Gul Rahim, Sudha Amarnath
Publikováno v:
Blood. 132:1242-1242
Background:Venous thromboembolism (VTE) is a highly prevalent complication of cancer and its treatment and is commonly treated with anticoagulation1. However, there are limited data regarding the use of therapeutic anticoagulation in patients with br
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Autor:
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Christopher R. Flowers, Jeffrey M. Switchenko
Publikováno v:
Blood. 134:3416-3416
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. Patients exhibit a 30%-40% relapse/refractory rate on standard first-line therapy and are known to have poor outcomes with relapsed/refractory disease, indicating a
Autor:
Suzanne R. Hayman, Morie A. Gertz, Steven R. Zeldenrust, Francis K. Buadi, Miriam Hobbs, Moritz Binder, Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Wilson I. Gonsalves, Ronald S. Go, Prashant Kapoor, John A. Lust, Robert A. Kyle, Taxiarchis Kourelis, S. Vincent Rajkumar, Rahma Warsame, Amie Fonder, Stephen J. Russell, Nelson Leung, Arjun Lakshman, Lisa Hwa
Publikováno v:
Blood. 132:4497-4497
Background: The introduction of novel therapeutics has led to improved outcomes in patients with multiple myeloma (MM). MM and its precursor lesion smoldering multiple myeloma (SMM) have traditionally been associated with increased mortality despite
Autor:
Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc, Karen R. Rabin, Kelly D. Getz, Jennifer J. Wilkes, Viviane C. Cahen, Yimei Li, Lena E. Winestone, Amanda M. DiNofia, M. Monica Gramatges, Alix E. Seif, Caitlin W Elgarten
Publikováno v:
Blood. 132:624-624
Administrative databases can be used to study outcomes including patients outside of clinical trials and have been used to identify relapse and HSCT in adult and adolescent/young adult leukemia populations. However, there are no published studies usi
Autor:
Binal N. Shah, Rasha Raslan, Jin Han, Michel Gowhari, Andrew Srisuwananukorn, Xu Zhang, Robert E. Molokie, Santosh L. Saraf, Victor R. Gordeuk
Publikováno v:
Blood Adv
Sickle cell disease (SCD) is an inherited red blood cell disorder that leads to vaso-occlusion, endothelial damage, and activation of pro-coagulant pathways. Recent studies have demonstrated that thrombotic episodes occur at a 3- to 100-fold higher r
Autor:
Nicholas Finn, Nancy Zhu, Martha Lenis, Lisa Chodirker, Brian Leber, Mary-Margaret Keating, Michelle Geddes, Danielle N. Blunt, Kenneth Rockwood, Jill Fulcher, Robert Delage, Versha Banerji, Karen W.L. Yee, Rena Buckstein, Eve St-Hilaire, Mitchell Sabloff, Liying Zhang, Richard A. Wells, Alexandre Mamedov, Mohamed Elemary, April Shamy, Heather A. Leitch
Publikováno v:
Blood. 132:4850-4850
Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic syndrome (MDS). We have previously shown that HRQoL remains stable over time and low hemoglobin, transfusion dependence (TD) and age > 65 years impact Q
Autor:
Veronika Buxhofer-Ausch, Marco Ruggeri, Tiziano Barbui, Ayalew Tefferi, Juergen Thiele, Valerio De Stefano, Maria Luigia Randi, Guido Finazzi, Elisa Rumi, Alessandro Rambaldi, Heinz Gisslinger, Silvia Betti, Francesco Passamonti, Irene Bertozzi, Francesco Rodeghiero, Alessandro M. Vannucchi, Alessandra Carobbio
Publikováno v:
Blood. 120:5128-5133
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories
Autor:
Leslie A. Andritsos, Natarajan Muthusamy, Qiuhong Zhao, John C. Byrd, Jennifer A. Woyach, Heather Breidenbach, Jeffrey Jones, Amber Gordon, Meixiao Long, Nyla A. Heerema, Caitlin Coombes, Farrukh T. Awan, Amy S. Ruppert
Publikováno v:
Blood. 128:4372-4372
Chronic Lymphocytic Leukemia (CLL) has a varied clinical course; some patients experience a long survival and others succumb to disease in a short time. Clinical factors correlated with either time to first treatment (TFT) and/or overall survival inc